▲ +247.56% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Theratechnologies in the last 3 months. The average price target is $7.13, with a high forecast of $11.00 and a low forecast of $2.00. The average price target represents a 247.56% upside from the last price of $2.05.
The current consensus among 4 polled investment analysts is to buy stock in Theratechnologies.
Theratechnologies Inc., a biopharmaceutical company, markets prescription products in the United States, Europe, and Canada. It offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. The company's pipeline products include F8 Formulation that could be used for the treatment of HIV-associated lipodystrophy; TH-1902 for the treatment of triple negative breast cancer; and TH-1904 for the treatment of ovarian cancer. The company was founded in 1993 and is headquartered in Montreal, Canada.